HOME >> BIOLOGY >> NEWS
New prime-boost HIV vaccine strategy shows promise in monkeys

A team of academic and government researchers reports today on a promising new "prime-boost" HIV vaccine approach that is currently on a development fast-track for human clinical trials. This vaccination strategy kept an HIV-like virus in check in monkeys, even when the animals were exposed to very high virus doses months after immunization. The study appears March 9 in Science Express, an online publication of the journal Science.

Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), which funded the research, praises the recent findings. "This latest study provides some of the best evidence to date that a preventive HIV vaccine may protect against AIDS. Although the vaccine did not prevent infection, it continues to keep the virus at nearly undetectable levels for at least several months. We do not yet know if this vaccine will work in humans, but plans for the necessary clinical studies are under way."

Scientists from Atlanta's Emory University and NIAID combined two vaccines in a strategy they hoped might be effective and then evaluated that strategy in monkeys. Both vaccines were designed against SHIV, a virus containing components of HIV and the related monkey virus, simian immunodeficiency virus (SIV). SHIV mimics HIV infection and causes serious illness in macaque monkeys. The hybrid virus allows researchers to study the reactions of the immune system to the vaccines and the virus.

In the study reported today, 23 of 24 vaccinated monkeys suppressed the virus to nearly undetectable levels during the 20-week follow-up. Virus levels in the one animal were intermittently higher but still more than 100 times lower than those in four control animals that had not received the vaccine. By 28 weeks, all four control animals had developed AIDS-related opportunistic infections and were euthanized, whereas all 24 animals receiving vaccine remain alive and healthy.

The Emory team develope
'"/>

Contact: Gregory Roa
greg.roa@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
7-Mar-2001


Page: 1 2 3

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
3. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
4. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
5. Protective gene may enhance vaccine responses
6. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
7. New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine
8. Growing new breed of vaccine-producing plants to fight human diseases worldwide
9. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
10. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
11. Herpes tool allows researchers to customize Alzheimers vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2020)... ... 2020 , ... Crystal Diagnostics (CDx) announced today that the ... to proprietary liquid crystal technology for rapid and accurate detection of foodborne pathogens. ... December 3, 2019. Together, these patents protect the company’s liquid crystal technology currently ...
(Date:2/1/2020)... VANCOUVER, British Columbia (PRWEB) , ... February 01, 2020 , ... ... people around the world and about 700,000 die from the disease. HCC is the ... occupies the first place among all countries when it comes to incidence of HCC, ...
(Date:1/29/2020)... RESEARCH TRIANGLE PARK, N.C. (PRWEB) , ... January ... ... as a partner to lead the new Analytics and Data Sciences practice, providing ... life sciences clients. Burke’s appointment was announced by Mike Townley, co-founder and Managing ...
Breaking Biology News(10 mins):
(Date:1/27/2020)... ... 2020 , ... Valencell, the leading innovator in wearable biometric ... Halma plc , a FTSE 100 global group of life-saving technology companies, ... Joshua Fund. A representative from Halma will join the Valencell board of directors. ...
(Date:1/24/2020)... Va. (PRWEB) , ... January 24, 2020 , ... ... other innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services ... of millions of people around the world. And as Slone Partners ...
(Date:1/23/2020)... ... , ... Ideal Implant CEO and President Robert S Hamas, ... American investor forums specializing in medical advancements. New technology was presented to US ... November 21, 2019 in New York City, and the Aesthetic Technology Summit in ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... of Darrell Taylor as Southern Midwest Region Industrial and Institutional (I&I) Account Manager. ... product line. , Darrell brings over 30 years of sales experience ...
Breaking Biology Technology:
Cached News: